Disease Overview
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: ● Clinical > ● Mechanistic > ● Correlative.
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| SALVIANOLIC ACID B | ? unclear | Mechanistic | DGIdb | |
| CANDOXATRIL | ? unclear | Mechanistic | DGIdb | |
| CILAZAPRIL | ↓ inhibits | Mechanistic | DGIdb | |
| TP0556351 | ↓ inhibits | Mechanistic | DGIdb | |
| PRAVASTATIN SODIUM | ? unclear | Mechanistic | DGIdb | |
| SILDENAFIL | ? unclear | Mechanistic | DGIdb | |
| GEMFIBROZIL | ? unclear | Mechanistic | DGIdb | |
| RESCINNAMINE | ? unclear | Mechanistic | DGIdb | |
| SPIRAPRIL | ? unclear | Mechanistic | DGIdb | |
| INDOMETHACIN | ? unclear | Mechanistic | DGIdb | |
| HYDROCHLOROTHIAZIDE | ? unclear | Mechanistic | DGIdb | |
| ARGIPRESSIN | ? unclear | Mechanistic | DGIdb | |
| METOPROLOL | ? unclear | Mechanistic | DGIdb | |
| DELAPRIL | ↓ inhibits | Mechanistic | DGIdb | |
| ACETYLCHOLINE | ? unclear | Mechanistic | DGIdb | |
| THERAPEUTIC GLUCOCORTICOID | ? unclear | Mechanistic | DGIdb | |
| IMIDAPRIL | ↓ inhibits | Mechanistic | DGIdb | |
| MALATHION | ↓ inhibits | Mechanistic | DGIdb | |
| MOEXIPRIL | ? unclear | Mechanistic | 56.0 nM (IC50) | DGIdb |
| VORINOSTAT | ? unclear | Mechanistic | DGIdb | |
| ILEPATRIL | ↓ inhibits | Mechanistic | DGIdb | |
| RXP470.1 | ↓ inhibits | Mechanistic | DGIdb | |
| CGS-27023A | ? unclear | Mechanistic | DGIdb | |
| NITROPRUSSIDE | ? unclear | Mechanistic | DGIdb | |
| ENALAPRILAT ANHYDROUS | ↓ inhibits | Mechanistic | 1.2 nM (IC50) | DGIdb |
| TORSEMIDE | ? unclear | Mechanistic | DGIdb | |
| ATORVASTATIN CALCIUM TRIHYDRATE | ? unclear | Mechanistic | DGIdb | |
| FOSINOPRIL | ? unclear | Mechanistic | DGIdb | |
| FUROSEMIDE | ? unclear | Mechanistic | DGIdb | |
| TEMOCAPRIL HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| BENAZEPRIL HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| CARBARIL | ↓ inhibits | Mechanistic | DGIdb | |
| BUPROPION HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| QUINAPRIL | ? unclear | Mechanistic | 8.3 nM (IC50) | DGIdb |
| COMPOUND 1 [PMID: 24900526] | ↓ inhibits | Mechanistic | DGIdb | |
| COMPOUND 20 [PMID: 22153340] | ↓ inhibits | Mechanistic | DGIdb | |
| BUMETANIDE | ? unclear | Mechanistic | DGIdb | |
| GALLOPAMIL | ? unclear | Mechanistic | DGIdb | |
| FLUOXETINE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| AZD6605 | ↓ inhibits | Mechanistic | DGIdb |
Showing top 40 of 229 agents ranked by evidence tier.
AGTR1
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| CANDESARTAN CILEXETIL | ↓ inhibits | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL586135 | ? unclear | Mechanistic | DGIdb | |
| VALSARTAN | ↓ inhibits | Mechanistic | 4700.0 nM (Ki) | DGIdb |
| EPROSARTAN MESYLATE | ↓ inhibits | Mechanistic | DGIdb | |
| FIMASARTAN | ↓ inhibits | Mechanistic | DGIdb | |
| ASCORBIC ACID | ? unclear | Mechanistic | DGIdb | |
| OLMESARTAN MEDOXOMIL | ↓ inhibits | Mechanistic | DGIdb | |
| AZILSARTAN MEDOXOMIL | ↓ inhibits | Mechanistic | DGIdb | |
| THERAPEUTIC ANDROSTANOLONE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL347610 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL421088 | ? unclear | Mechanistic | DGIdb | |
| LOSARTAN POTASSIUM | ↓ inhibits | Mechanistic | 5.5 nM (IC50) | DGIdb |
| CHEMBL:CHEMBL1492017 | ? unclear | Mechanistic | DGIdb | |
| SPARSENTAN | ↓ inhibits | Mechanistic | DGIdb | |
| SODIUM CHLORIDE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL261693 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1972216 | ? unclear | Mechanistic | DGIdb | |
| EPROSARTAN | ? unclear | Mechanistic | 7.3 nM (IC50) | DGIdb |
| C-FOS ANTISENSE | ? unclear | Mechanistic | DGIdb | |
| SARALASIN ACETATE | ↓ inhibits | Mechanistic | DGIdb | |
| IRBESARTAN | ↓ inhibits | Mechanistic | 1.1 nM (Ki) | DGIdb |
| DISULFIRAM | ? unclear | Mechanistic | DGIdb | |
| SAPRISARTAN | ? unclear | Mechanistic | DGIdb | |
| H2O2 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL591834 | ? unclear | Mechanistic | DGIdb | |
| CAPTOPRIL | ? unclear | Mechanistic | DGIdb | |
| ANGIOTENSIN II | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL400912 | ? unclear | Mechanistic | DGIdb | |
| ATORVASTATIN CALCIUM TRIHYDRATE | ? unclear | Mechanistic | DGIdb | |
| IDOXIFENE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL528694 | ? unclear | Mechanistic | DGIdb | |
| IL-6 | ? unclear | Mechanistic | DGIdb | |
| ANGIOTENSIN II ACETATE | ↑ activates | Mechanistic | DGIdb | |
| LEVODOPA | ? unclear | Mechanistic | DGIdb | |
| GAMMA-INTERFERON | ? unclear | Mechanistic | DGIdb | |
| AZILSARTAN KAMEDOXOMIL | ↓ inhibits | Mechanistic | DGIdb | |
| HYDROCHLOROTHIAZIDE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1445650 | ? unclear | Mechanistic | DGIdb | |
| MUSCLE RELAXANT | ? unclear | Mechanistic | DGIdb | |
| CL-329167 | ? unclear | Mechanistic | DGIdb |
Showing top 40 of 249 agents ranked by evidence tier.
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| CISPLATIN | ? unclear | Mechanistic | DGIdb | |
| ZILTIVEKIMAB | ~ modulates | Mechanistic | DGIdb | |
| CHINESE HERBS | ? unclear | Mechanistic | DGIdb | |
| PF-04236921 | ↓ inhibits | Mechanistic | DGIdb | |
| MRA 003 US | ↓ inhibits | Mechanistic | DGIdb | |
| SIGNAL TRANSDUCTION INHIBITOR | ? unclear | Mechanistic | DGIdb | |
| BINETRAKIN | ? unclear | Mechanistic | DGIdb | |
| IBUDILAST | ? unclear | Mechanistic | DGIdb | |
| INSULIN, REGULAR, HUMAN | ? unclear | Mechanistic | DGIdb | |
| SILTUXIMAB | ↓ inhibits | Mechanistic | DGIdb | |
| METRONIDAZOLE | ? unclear | Mechanistic | DGIdb | |
| CLAZAKIZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| GALLIUM NITRATE | ? unclear | Mechanistic | DGIdb | |
| INTERFERON ALFA-2B | ? unclear | Mechanistic | DGIdb | |
| DULOXETINE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| MEDI-5117 | ↓ inhibits | Mechanistic | DGIdb | |
| GEMFIBROZIL | ? unclear | Mechanistic | DGIdb | |
| BIAFINE CREAM | ? unclear | Mechanistic | DGIdb | |
| ETANERCEPT | ? unclear | Mechanistic | DGIdb | |
| ELSILIMOMAB | ↓ inhibits | Mechanistic | DGIdb | |
| SAQUINAVIR | ? unclear | Mechanistic | DGIdb | |
| INFLIXIMAB | ? unclear | Mechanistic | DGIdb | |
| LINEZOLID | ? unclear | Mechanistic | DGIdb | |
| IFOSFAMIDE | ? unclear | Mechanistic | DGIdb | |
| OLOKIZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| HMG-COA REDUCTASE INHIBITOR | ? unclear | Mechanistic | DGIdb | |
| MIDOSTAURIN | ? unclear | Mechanistic | DGIdb | |
| SELENIUM | ? unclear | Mechanistic | DGIdb | |
| SIRUKUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| PEGINTERFERON ALFA-2B | ? unclear | Mechanistic | DGIdb | |
| ECHINACEA PREPARATION | ? unclear | Mechanistic | DGIdb | |
| ENZYME INHIBITOR | ? unclear | Mechanistic | DGIdb | |
| FENOFIBRATE MICRONIZED | ? unclear | Mechanistic | DGIdb | |
| VITAMIN K | ? unclear | Mechanistic | DGIdb | |
| PEGINTERFERON ALFA-2A | ? unclear | Mechanistic | DGIdb | |
| RIBAVIRIN | ? unclear | Mechanistic | DGIdb | |
| VITAMIN A PALMITATE | ? unclear | Mechanistic | DGIdb | |
| ARSENIC TRIOXIDE | ? unclear | Mechanistic | DGIdb | |
| DIHYDROSPHINGOSINE | ? unclear | Mechanistic | DGIdb | |
| LEVOFLOXACIN ANHYDROUS | ? unclear | Mechanistic | DGIdb |
Showing top 40 of 173 agents ranked by evidence tier.
INSR
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| TESOFENSINE | ? unclear | Mechanistic | DGIdb | |
| INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN | ↑ activates | Mechanistic | DGIdb | |
| GO-6976 | ? unclear | Mechanistic | DGIdb | |
| INSULIN ZINC, PROMPT | ↑ activates | Mechanistic | DGIdb | |
| INSULIN PURIFIED PORK | ↑ activates | Mechanistic | DGIdb | |
| INSULIN ZINC SUSP EXTENDED PURIFIED BEEF | ↑ activates | Mechanistic | DGIdb | |
| INSULIN ZINC, EXTENDED | ↑ activates | Mechanistic | DGIdb | |
| INSULIN ZINC SUSP EXTENDED BEEF | ↑ activates | Mechanistic | DGIdb | |
| INSULIN ZINC SUSP BEEF | ↑ activates | Mechanistic | DGIdb | |
| INSULIN SENSITIZER S-707106 | ? unclear | Mechanistic | DGIdb | |
| SP-600125 | ? unclear | Mechanistic | DGIdb | |
| CYCLOPHOSPHAMIDE ANHYDROUS | ? unclear | Mechanistic | DGIdb | |
| INSULIN DETEMIR | ↑ activates | Mechanistic | DGIdb | |
| INSULIN DEGLUDEC | ↑ activates | Mechanistic | DGIdb | |
| AEW-541 | ? unclear | Mechanistic | 2300.0 nM (IC50) | DGIdb |
| ILORASERTIB | ? unclear | Mechanistic | DGIdb | |
| NVP-TAE684 | ? unclear | Mechanistic | DGIdb | |
| INSULIN ASPART PROTAMINE RECOMBINANT | ↑ activates | Mechanistic | DGIdb | |
| INSULIN SUSP PROTAMINE ZINC PURIFIED BEEF | ↑ activates | Mechanistic | DGIdb | |
| INSULIN, PROTAMINE ZINC | ↑ activates | Mechanistic | DGIdb | |
| INSULIN TREGOPIL | ↑ activates | Mechanistic | DGIdb | |
| INSULIN, REGULAR, HUMAN | ↑ activates | Mechanistic | DGIdb | |
| PF-562271 | ? unclear | Mechanistic | DGIdb | |
| INSULIN SUSP PROTAMINE ZINC PURIFIED PORK | ↑ activates | Mechanistic | DGIdb | |
| RECOMBINANT HUMAN KALLIKREIN-1 | ? unclear | Mechanistic | DGIdb | |
| LINIFANIB | ? unclear | Mechanistic | DGIdb | |
| INSULIN [INJECTION], BIPHASIC | ↑ activates | Mechanistic | DGIdb | |
| INSULIN HUMAN, ISOPHANE | ↑ activates | Mechanistic | DGIdb | |
| INSULIN SUSP ISOPHANE PURIFIED PORK | ↑ activates | Mechanistic | DGIdb | |
| INSULIN ZINC SUSP PURIFIED PORK | ↑ activates | Mechanistic | DGIdb | |
| RG-1530 | ? unclear | Mechanistic | DGIdb | |
| EPIRUBICIN | ? unclear | Mechanistic | DGIdb | |
| INSULIN ASPART PROTAMINE, HUMAN | ↑ activates | Mechanistic | DGIdb | |
| TOZASERTIB | ? unclear | Mechanistic | 506.0 nM (Kd) | DGIdb |
| TOPIRAMATE | ? unclear | Mechanistic | DGIdb | |
| LINSITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| INSULIN LISPRO | ↑ activates | Mechanistic | DGIdb | |
| INSULIN LISPRO PROTAMINE RECOMBINANT | ↑ activates | Mechanistic | DGIdb | |
| INSULIN SUSP ISOPHANE BEEF/PORK | ↑ activates | Mechanistic | DGIdb | |
| MITOGLITAZONE | ? unclear | Mechanistic | DGIdb |
Showing top 40 of 256 agents ranked by evidence tier.
IRS1
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| AGANIRSEN | ? unclear | Mechanistic | DGIdb | |
| CYCLOPHOSPHAMIDE ANHYDROUS | ? unclear | Mechanistic | DGIdb | |
| FLUOROURACIL | ? unclear | Mechanistic | DGIdb | |
| DEHYDRATED ALCOHOL | ? unclear | Mechanistic | DGIdb | |
| PRASTERONE | ? unclear | Mechanistic | DGIdb | |
| EPIRUBICIN | ? unclear | Mechanistic | DGIdb | |
| INOSITOL | ? unclear | Mechanistic | DGIdb | |
| GLIMEPIRIDE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL1685056 | ↓ inhibits | Mechanistic | 50.0 nM (Kd) | ChEMBL |
| CHEMBL1685055 | ↓ inhibits | Mechanistic | 150.0 nM (Kd) | ChEMBL |
| CHEMBL1681823 | ↓ inhibits | Mechanistic | 50.0 nM (Kd) | ChEMBL |
| CHEMBL4536878 | ↓ inhibits | Mechanistic | 120.0 nM (Kd) | ChEMBL |
| CHEMBL4591779 | ↓ inhibits | Mechanistic | 16200.0 nM (Kd) | ChEMBL |
| CHEMBL4530453 | ↓ inhibits | Mechanistic | 1600.0 nM (Kd) | ChEMBL |
| CHEMBL1572640 | ↓ inhibits | Mechanistic | 3300.0 nM (Kd) | ChEMBL |
| CHEMBL4576057 | ↓ inhibits | Mechanistic | 16400.0 nM (Kd) | ChEMBL |
LEPR
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| MIBAVADEMAB | ↑ activates | Mechanistic | DGIdb | |
| SIMVASTATIN | ? unclear | Mechanistic | DGIdb | |
| VALPROIC ACID | ? unclear | Mechanistic | DGIdb | |
| METRELEPTIN | ↑ activates | Mechanistic | DGIdb | |
| ATORVASTATIN CALCIUM TRIHYDRATE | ? unclear | Mechanistic | DGIdb | |
| SETMELANOTIDE | ? unclear | Mechanistic | DGIdb |
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| INOSITOL | ? unclear | Mechanistic | DGIdb | |
| DEXTRAN SULFATE | ? unclear | Mechanistic | DGIdb | |
| ASPARAGINASE | ? unclear | Mechanistic | DGIdb | |
| RETINYL ACETATE | ? unclear | Mechanistic | DGIdb | |
| RECOMBINANT INTERLEUKIN | ? unclear | Mechanistic | DGIdb | |
| ANABOLIC STEROID | ? unclear | Mechanistic | DGIdb | |
| OXIDOPAMINE | ? unclear | Mechanistic | DGIdb | |
| ISOTRETINOIN | ? unclear | Mechanistic | DGIdb | |
| FOLIC ACID | ? unclear | Mechanistic | DGIdb | |
| LYMPHOKINE-ACTIVATED KILLER CELLS | ? unclear | Mechanistic | DGIdb | |
| MIFEPRISTONE | ? unclear | Mechanistic | DGIdb | |
| ACARBOSE | ? unclear | Mechanistic | DGIdb | |
| H2O2 | ? unclear | Mechanistic | DGIdb | |
| GEMFIBROZIL | ? unclear | Mechanistic | DGIdb | |
| RECOMBINANT LYMPHOKINE | ? unclear | Mechanistic | DGIdb | |
| CLOFIBRATE | ? unclear | Mechanistic | DGIdb | |
| TRIAMCINOLONE | ? unclear | Mechanistic | DGIdb | |
| ADRIAMYCIN | ? unclear | Mechanistic | DGIdb | |
| LABETALOL | ? unclear | Mechanistic | DGIdb | |
| LOVASTATIN | ? unclear | Mechanistic | DGIdb | |
| INSULIN, REGULAR, HUMAN | ? unclear | Mechanistic | DGIdb | |
| DIAZOXIDE | ? unclear | Mechanistic | DGIdb | |
| PIOGLITAZONE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| PRAVASTATIN SODIUM | ? unclear | Mechanistic | DGIdb | |
| RESERPINE | ? unclear | Mechanistic | DGIdb | |
| ORLISTAT | ? unclear | Mechanistic | 66.0 nM (IC50) | DGIdb |
| NADOLOL | ? unclear | Mechanistic | DGIdb | |
| IBROLIPIM | ? unclear | Mechanistic | DGIdb | |
| CHEMBL339297 | ↓ inhibits | Mechanistic | 200.0 nM (IC50) | ChEMBL |
| TOLYL BORONIC ACID | ↓ inhibits | Mechanistic | 9000.0 nM (IC50) | ChEMBL |
| CHEMBL1952294 | ↓ inhibits | Mechanistic | 9000.0 nM (IC50) | ChEMBL |
| CHEMBL1952295 | ↓ inhibits | Mechanistic | 8000.0 nM (IC50) | ChEMBL |
| CHEMBL1952296 | ↓ inhibits | Mechanistic | 15000.0 nM (IC50) | ChEMBL |
| CHEMBL1952297 | ↓ inhibits | Mechanistic | 30000.0 nM (IC50) | ChEMBL |
| CHEMBL485946 | ↓ inhibits | Mechanistic | 42000.0 nM (IC50) | ChEMBL |
| CHEMBL1952298 | ↓ inhibits | Mechanistic | 50000.0 nM (IC50) | ChEMBL |
| CHEMBL1952299 | ↓ inhibits | Mechanistic | 50000.0 nM (IC50) | ChEMBL |
| CHEMBL1952302 | ↓ inhibits | Mechanistic | 25000.0 nM (IC50) | ChEMBL |
| CHEMBL1952303 | ↓ inhibits | Mechanistic | 50000.0 nM (IC50) | ChEMBL |
| CHEMBL1952304 | ↓ inhibits | Mechanistic | 55000.0 nM (IC50) | ChEMBL |
Showing top 40 of 60 agents ranked by evidence tier.
PPARG
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| METHOXYCHLOR | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL2208197 | ? unclear | Mechanistic | DGIdb | |
| PROPYLPYRAZOLETRIOL | ? unclear | Mechanistic | DGIdb | |
| LANIFIBRANOR | ↑ activates | Mechanistic | DGIdb | |
| PROPYLPARABEN | ? unclear | Mechanistic | DGIdb | |
| ABIETIC ACID | ? unclear | Mechanistic | DGIdb | |
| KEPONE | ? unclear | Mechanistic | DGIdb | |
| SPIRONOLACTONE | ? unclear | Mechanistic | DGIdb | |
| FLUOXASTROBIN | ? unclear | Mechanistic | DGIdb | |
| ROSIGLITAZONE MALEATE | ↑ activates | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL2178583 | ? unclear | Mechanistic | DGIdb | |
| NAVEGLITAZAR | ↑ activates | Mechanistic | DGIdb | |
| CELECOXIB | ? unclear | Mechanistic | DGIdb | |
| SHINPTEROCARPIN | ? unclear | Mechanistic | DGIdb | |
| PSAMMAPLIN A | ? unclear | Mechanistic | DGIdb | |
| TECNAZENE | ? unclear | Mechanistic | DGIdb | |
| MYCOPHENOLATE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1833984 | ? unclear | Mechanistic | DGIdb | |
| IMIGLITAZAR | ↑ activates | Mechanistic | DGIdb | |
| ROSIGLITAZONE | ? unclear | Mechanistic | 250.0 nM (IC50) | DGIdb |
| CLX-0921 | ↑ activates | Mechanistic | DGIdb | |
| AVE0847 | ↑ activates | Mechanistic | DGIdb | |
| CHLORFENAPYR | ? unclear | Mechanistic | DGIdb | |
| PIOGLITAZONE HYDROCHLORIDE | ↑ activates | Mechanistic | DGIdb | |
| PROCHLORAZ | ? unclear | Mechanistic | DGIdb | |
| MESALAMINE | ↑ activates | Mechanistic | DGIdb | |
| BEZAFIBRATE | ↑ activates | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL312032 | ? unclear | Mechanistic | DGIdb | |
| ISOSILYBIN A | ? unclear | Mechanistic | DGIdb | |
| AMORFRUTIN A | ? unclear | Mechanistic | DGIdb | |
| NALED | ? unclear | Mechanistic | DGIdb | |
| TROGLITAZONE | ↑ activates | Mechanistic | 302.0 nM (Ki) | DGIdb |
| PROSTAGLANDIN D2 | ? unclear | Mechanistic | DGIdb | |
| INT131 | ~ modulates | Mechanistic | DGIdb | |
| EFATUTAZONE HYDROCHLORIDE | ↑ activates | Mechanistic | DGIdb | |
| FLUORODIFEN | ? unclear | Mechanistic | DGIdb | |
| FLUDIOXONIL | ? unclear | Mechanistic | DGIdb | |
| ESTRADIOL VALERATE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL166112 | ? unclear | Mechanistic | DGIdb | |
| BENSULIDE | ? unclear | Mechanistic | DGIdb |
Showing top 40 of 231 agents ranked by evidence tier.
PRKAA1
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| GW441756X | ? unclear | Mechanistic | DGIdb | |
| PD-0166285 | ? unclear | Mechanistic | 316.23 nM (Ki) | DGIdb |
| CENISERTIB | ? unclear | Mechanistic | DGIdb | |
| CYC-116 | ? unclear | Mechanistic | 501.19 nM (Ki) | DGIdb |
| PENTOSTATIN | ? unclear | Mechanistic | DGIdb | |
| PALBOCICLIB | ? unclear | Mechanistic | DGIdb | |
| JNJ-7706621 | ? unclear | Mechanistic | 1700.0 nM (Kd) | DGIdb |
| PF-562271 | ? unclear | Mechanistic | DGIdb | |
| TOZASERTIB | ? unclear | Mechanistic | 1100.0 nM (Kd) | DGIdb |
| STREPTOZOCIN | ? unclear | Mechanistic | DGIdb | |
| DOVITINIB | ? unclear | Mechanistic | 520.0 nM (Kd) | DGIdb |
| TYROSINE KINASE INHIBITOR | ? unclear | Mechanistic | DGIdb | |
| METFORMIN | ? unclear | Mechanistic | DGIdb | |
| RG-1530 | ? unclear | Mechanistic | DGIdb | |
| LY-2090314 | ? unclear | Mechanistic | 630.96 nM (Ki) | DGIdb |
| ADENOSINE DEAMINASE INHIBITOR | ? unclear | Mechanistic | DGIdb | |
| SAPONARIN | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL587615 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1997335 | ? unclear | Mechanistic | DGIdb | |
| ENTRECTINIB | ? unclear | Mechanistic | 251.19 nM (Ki) | DGIdb |
| SIROLIMUS | ? unclear | Mechanistic | DGIdb | |
| ILORASERTIB | ? unclear | Mechanistic | DGIdb | |
| TETRADECANOYLPHORBOL ACETATE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL379975 | ? unclear | Mechanistic | DGIdb | |
| HESPERADIN | ↓ inhibits | Mechanistic | 19.0 nM (Kd) | DGIdb |
| PHENFORMIN | ? unclear | Mechanistic | DGIdb | |
| THYROXINE | ? unclear | Mechanistic | DGIdb | |
| ACADESINE | ↑ activates | Mechanistic | DGIdb | |
| CHEMOPREVENTIVE AGENT | ? unclear | Mechanistic | DGIdb | |
| SOTRASTAURIN | ? unclear | Mechanistic | 630.96 nM (Ki) | DGIdb |
| NVP-TAE684 | ? unclear | Mechanistic | DGIdb | |
| METFORMIN HYDROCHLORIDE | ↑ activates | Mechanistic | DGIdb | |
| SUNITINIB | ↓ inhibits | Mechanistic | 52.0 nM (Kd) | ChEMBL |
| ALVOCIDIB | ↓ inhibits | Mechanistic | 6600.0 nM (Kd) | ChEMBL |
| STAUROSPORINE | ↓ inhibits | Mechanistic | 9.0 nM (Kd) | ChEMBL |
| VANDETANIB | ↓ inhibits | Mechanistic | 10000.0 nM (Kd) | ChEMBL |
| AST-487 | ↓ inhibits | Mechanistic | 1400.0 nM (Kd) | ChEMBL |
| RAF-265 | ↓ inhibits | Mechanistic | 4500.0 nM (Kd) | ChEMBL |
| MIDOSTAURIN | ↓ inhibits | Mechanistic | 180.0 nM (Kd) | ChEMBL |
| SU-014813 | ↓ inhibits | Mechanistic | 100.0 nM (Kd) | ChEMBL |
Showing top 40 of 202 agents ranked by evidence tier.
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| NERELIMOMAB | ↓ inhibits | Mechanistic | DGIdb | |
| CROMOLYN SODIUM | ? unclear | Mechanistic | DGIdb | |
| PLACULUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| METHYLENE BLUE | ? unclear | Mechanistic | DGIdb | |
| ALTEPLASE | ? unclear | Mechanistic | DGIdb | |
| CARBOPLATIN | ? unclear | Mechanistic | DGIdb | |
| GENTAMICIN | ? unclear | Mechanistic | DGIdb | |
| GOLIMUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| BUPIVACAINE | ? unclear | Mechanistic | DGIdb | |
| PENTOXIFYLLINE | ? unclear | Mechanistic | 85000.0 nM (IC50) | DGIdb |
| BENZO[E]PYRENE | ? unclear | Mechanistic | DGIdb | |
| THALIDOMIDE | ? unclear | Mechanistic | DGIdb | |
| PYRAZINAMIDE | ? unclear | Mechanistic | DGIdb | |
| GLIMEPIRIDE | ? unclear | Mechanistic | DGIdb | |
| OMEPRAZOLE | ? unclear | Mechanistic | DGIdb | |
| LENERCEPT | ↓ inhibits | Mechanistic | DGIdb | |
| ADALIMUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| PRAZOSIN HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| REMTOLUMAB | ? unclear | Mechanistic | DGIdb | |
| MIDOSTAURIN | ? unclear | Mechanistic | DGIdb | |
| LENABASUM | ? unclear | Mechanistic | DGIdb | |
| MAGNESIUM SULFATE ANHYDROUS | ? unclear | Mechanistic | DGIdb | |
| PICIBANIL | ? unclear | Mechanistic | DGIdb | |
| FLUOCINOLONE ACETONIDE | ? unclear | Mechanistic | DGIdb | |
| MILTEFOSINE | ? unclear | Mechanistic | DGIdb | |
| HOMIDIUM BROMIDE | ? unclear | Mechanistic | DGIdb | |
| OZORALIZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| PEGSUNERCEPT | ↓ inhibits | Mechanistic | DGIdb | |
| CERTOLIZUMAB PEGOL | ↓ inhibits | Mechanistic | DGIdb | |
| THERAPEUTIC HORMONE | ? unclear | Mechanistic | DGIdb | |
| NAFAMOSTAT | ? unclear | Mechanistic | DGIdb | |
| FOLIC ACID | ? unclear | Mechanistic | DGIdb | |
| ABBV-257 | ? unclear | Mechanistic | DGIdb | |
| RISPERIDONE | ? unclear | Mechanistic | DGIdb | |
| COVA322 | ? unclear | Mechanistic | DGIdb | |
| HYDROXYCHLOROQUINE | ? unclear | Mechanistic | DGIdb | |
| CERTOLIZUMAB | ? unclear | Mechanistic | DGIdb | |
| AN0128 | ? unclear | Mechanistic | DGIdb | |
| 5,7-DIHYDROXY-4-METHYLCOUMARIN | ? unclear | Mechanistic | DGIdb | |
| SORAFENIB | ? unclear | Mechanistic | DGIdb |
Showing top 40 of 277 agents ranked by evidence tier.
Recruiting and recently completed trials from ClinicalTrials.gov. Data retrieved 2026-07-03.
Smith-Lemli-Opitz Syndrome (SLOS) is a genetic disorder (autosomal recessive) caused by an abnormality in the production of cholesterol. The disorder can occur in both a "mild" or "severe" form. SLOS is associated with multiple birth defects and mental retardation. Some of the birth defects include;...
Hermansky-Pudlak Syndrome (HPS) is an inherited disease which results in decreased pigmentation (oculocutaneous albinism), bleeding problems due to a platelet abnormality (platelet storage pool defect), and storage of an abnormal fat-protein compound (lysosomal accumulation of ceroid lipofuscin). T...
The etiology of pulmonary fibrosis is unknown. Analyses of blood, genomic DNA, and specimens procured by bronchoscopy, lung biopsy, lung transplantation, clinically-indicated extra-pulmonary biopsies, or post-mortem examination from individuals with this disorder may contribute to our understanding ...
This study will investigate the cause and medical problems associated with a group of genetic disorders known as inborn errors of cholesterol synthesis, in which the body does not produce cholesterol. People with this disorder may have birth defects and learning and behavioral problems. People with...
This study being done to learn more about the use of medical Magnetic Resonance Imaging (mMRI) and dedicated dental MRI (ddMRI) as a non-invasive diagnosing tool when evaluating potential oral cancerous and precancerous lesions in Fanconi Anemia patients.
This phase III trial studies combination chemotherapy and atezolizumab to see how well it works compared with combination chemotherapy alone in treating patients with stage III colon cancer and deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR). Drugs used in combination chemotherapy, such...
Background: Research studies have shown that genetic changes and family history may increase a man s risk for prostate cancer. Researchers want to follow the prostate health of men who have specific genetic changes associated with prostate cancer to help them learn more about which men are at highe...
The purpose of the study is to assess the bioavailability, mass balance, pharmacokinetics, metabolism and excretion of radiolabeled (14C) VH4524184.
Methylmalonic acidemia (MMA), one of the most common inborn errors of organic acid metabolism, is heterogeneous in etiology and clinical manifestations. Affected patients with cblA, cblB and mut classes of MMA are medically fragile and can suffer from complications such as metabolic stroke or infarc...
The primary outcome of interest is change in PCOS health-related quality of life, while the secondary outcome of interest is change in adiposity, cardiometabolic, and inflammation biomarkers.
The full HER CROWN will be a prospective cohort study to propose a novel, women-specific cardiovascular risk score/ algorithm in the prediction of hard cardiovascular outcomes (myocardial infarction, unstable angina, coronary revascularization, stroke, total and cardiovascular mortality). This futur...
This research is being done to learn if a new type of haploidentical transplantation using TCR alpha beta and CD19 depleted stem cell graft from the donor is safe and effective to treat the patient's underlying condition. This study will use stem cells obtained via peripheral blood or bone marrow fr...
The primary efficacy objective of the trial is to assess the ability of TEV-53408 to attenuate gluten-induced enteropathy in adults with celiac disease. The primary safety objective of the trial is to assess the safety of TEV-53408 in adults with celiac disease. A secondary objective is to further...
Background: \- Researchers are interested in studying individuals who have known or suspected metabolic, inflammatory or genetic diseases that may put them at a high risk for heart diseases or diseases of their blood vessels. Depending on the condition being studied, both affected and nonaffected i...
Early Check provides voluntary screening of newborns for a selected panel of conditions. The study has three main objectives: 1) develop and implement an approach to identify affected infants, 2) address the impact on infants and families who screen positive, and 3) evaluate the Early Check program....
Searched directly from “Metabolic Syndrome” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 10-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).
Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."